Full Breakdown
Eli Lilly Secures $1.9 B Deal with Ascidian Therapeutics to Advance RNA-Based Kidney Disease Therapies
6/4/2026, 2:06:45 AM
Core Deal Overview
On June 3 2026, Eli Lilly announced a global research and licensing agreement with Boston-based Ascidian Therapeutics. The partnership grants Lilly exclusive rights to Ascidian’s RNA-exon-editing platform for undisclosed monogenic kidney-disease targets. In return, Ascidian will receive up to $1.9 billion in an undisclosed upfront payment, milestone-linked development and regulatory payments, and tiered royalties on future product sales. Ascidian will lead discovery and early pre-clinical work; Lilly will assume later-stage pre-clinical development, clinical trials, manufacturing, and commercialization.
Background & Context
RNA-exon editing is positioned as a safer alternative to DNA-editing tools such as CRISPR because it rewrites faulty genetic instructions at the RNA level without permanent genome alteration. Over the past year, Lilly has accelerated its entry into genetic medicines, acquiring Verve Therapeutics for $1.13 billion and forming partnerships with Profluent, Seamless Therapeutics, and others. Ascidian, which launched its platform in 2022, previously licensed the technology to Roche for neurological programs and has an early-human trial for Stargardt disease.
Key Figures & Organizations
- Eli Lilly (LLY.N) – Indiana-based pharmaceutical giant, responsible for advanced development and market launch.
- Ascidian Therapeutics – Boston biotech specializing in RNA-exon-editing.
- Michael Ehlers – CEO, Ascidian.
- Daniel Rosan – Chief Business Officer (also described as chief financial and business officer) of Ascidian.
- Robert Bell – Chief Scientific Officer, Ascidian.
Data & Statistics
- More than 60 genetically driven kidney diseases affect millions worldwide.
- Over 3.5 million U.S. residents suffer from severe inherited kidney disease, with current care limited to symptom management, dialysis, or transplantation.
- The deal’s total potential value: $1.9 billion (upfront, milestones, royalties).
- Ascidian’s prior Roche collaboration provided a $42 million upfront payment and could yield up to $1.8 billion in milestones.
Why It Matters
Inherited kidney disorders lack disease-modifying therapies. By targeting disease-causing exons at the RNA level, the platform aims to correct the underlying protein defect while avoiding permanent DNA changes and the delivery challenges of viral vectors. If successful, the approach could shift treatment from supportive care to a curative model, reducing the clinical and economic burden of dialysis and transplantation.
Official Statements & Responses
Ascidian executives emphasized that the collaboration combines the biotech’s RNA-editing expertise with Lilly’s genetic-medicine capabilities to “dramatically reduce the burden of genetic kidney disease.” Both companies framed the partnership as a response to the unmet need for effective treatments for monogenic kidney conditions, describing the RNA-based strategy as “compelling” and “ready for tractability.”
Conflicting Reports & Gaps
- The specific kidney-disease targets remain undisclosed.
- The size of the upfront payment is not public.
- Milestone criteria and timelines have not been detailed.
- No independent efficacy data for the platform in kidney disease are available at this stage.
Verbatim Quotes
- “We think (Ascidian's technology) has many of the benefits of a traditional CRISPR or DNA editing technology, but with the key advantage of not actually altering the ?patient's DNA, only changing RNA,” — Daniel Rosan, Chief Business Officer, Ascidian Therapeutics
- “Combined with Lilly's genetic medicine expertise, we aim to dramatically reduce the burden of genetic kidney disease,” — Michael Ehlers, CEO, Ascidian Therapeutics
- “Lilly and Ascidian believe that patients with serious monogenic kidney diseases deserve effective treatment options and that an RNA-based approach is a compelling strategy for those diseases,” — Michael Ehlers, CEO, Ascidian Therapeutics
- “Lilly is both a radar and a magnet in genetic medicines,” — Daniel Rosan, Chief Business Officer, Ascidian Therapeutics
What’s Next
Ascidian will advance discovery and early pre-clinical studies on the initial kidney targets. Upon achieving predefined milestones, Lilly will transition projects into later-stage pre-clinical work, followed by Phase I-III clinical trials. Successful candidates will move to manufacturing and global commercialization under Lilly’s portfolio, while Ascidian retains rights to explore additional kidney-disease programs independently or with other partners.
